Goldline Pharmaceutical Ltd (GLPL) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Goldline Pharmaceutical Ltd on NSE and BSE, with an AI summary of each filing.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Amol Mujumdar
Acquisition/ Disposal of Shares · 02 Sept 2026, 4:42 pm
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Amol Mujumdar
Acquisition/ Disposal of Shares · 02 Sept 2026, 4:39 pm
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Amol Laxmikant Mujumdar
Acquisition/ Disposal of Shares · 01 Sept 2026, 6:41 pm
Promoter Increases Stake in Goldline Pharmaceutical Amol Laxmikant Mujumdar, Promoter and Managing Director, acquired 60,000 equity shares (0.62% of total capital) via an open market purchase on 31 Aug'26. This transaction increases his total shareholding from 2,749,988 shares (28.64%) to 2,809,988 shares (29.27%). The purchase signals strengthened promoter confidence. The company's total issued capital remains at 9,600,000 equity shares post-acquisition. This disclosure was made under SEBI (SAST) Regulations, 2011.
Scrutinizer Report
Annual General Meeting · 31 Aug 2026, 10:38 pm
Goldline Pharmaceutical AGM: All Resolutions Passed With Unanimous Shareholder Support At its AGM on 29-Aug-26, Goldline Pharmaceutical shareholders approved all eight proposed resolutions with 100% of valid votes cast in favor. Key approvals include adopting the audited financials for FY26, declaring a dividend on preference shares, and re-appointing a director. Shareholders also sanctioned material related party transactions and two special resolutions for borrowing unsecured loans from directors and approving loans/investments under Section 185 of the Companies Act, 2013. Overall voter turnout represented 61.11% of total outstanding shares, with no votes cast against any resolution.
AGM Proceedings of the 22nd Annual General Meeting (AGM) of the Company pertaining to Financial Year 2025-26.
Annual General Meeting · 30 Aug 2026, 2:31 am
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Swapan Khandelwal
Acquisition/ Disposal of Shares · 29 Aug 2026, 10:34 pm
Promoter Increases Stake in Goldline Pharmaceutical Mr. Swapan Khandelwal, a Promoter and Whole Time Director of Goldline Pharmaceutical, acquired 78,000 equity shares via an open market purchase on 28th Aug'26. This transaction represents 0.81% of the company's total paid-up share capital. Following the acquisition, his total shareholding in the company increased from 29.27% (2,809,988 shares) to 30.08% (2,887,988 shares), signaling a strengthening of promoter conviction. The total equity share capital of the company remained at 9,600,000 shares post-transaction.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Swapan Khandelwal
Acquisition/ Disposal of Shares · 29 Aug 2026, 10:33 pm
Promoter Increases Stake in Goldline Pharmaceutical Mr. Swapan Khandelwal, a Promoter and Whole Time Director, acquired 78,000 equity shares via an open market purchase on 28th Aug'26. This transaction represents 0.81% of the company's paid-up share capital. Following the acquisition, Mr. Khandelwal's total holding in Goldline Pharmaceutical has increased from 29.27% (2,809,988 shares) to 30.08% (2,887,988 shares). The promoter's increased stake signals a strengthening of insider confidence in the company's prospects.
Submission of Annual Report of Goldline Pharmaceutical Limited for FY 2025-26.
Others (Uncategorized) · 07 Aug 2026, 12:40 am
Intimation of notice of 22nd AGM of Goldline Pharmaceutical Limited.
Annual General Meeting · 07 Aug 2026, 12:27 am
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prashant Shrikrishna Karkare
Acquisition/ Disposal of Shares · 30 Jul 2026, 1:51 pm
Executive Director Increases Stake via Open Market Purchase Goldline Pharmaceutical's Executive Director, Mr. Prashant Shrikrishna Karkare, acquired 27,000 equity shares through an open market purchase on 28th Jul'26. This transaction represents 0.28% of the company's total issued and paid-up share capital. Following the acquisition, Mr. Karkare's total holding increased from 3 shares (0.00%) to 27,003 shares (0.28%). The disclosure was made pursuant to SEBI's SAST Regulations, 2011. Mr. Karkare is not part of the promoter group.
Appointment of M/s. Avinash Prakash Gandhewar, Practicing Company Secretaries, Membership No. FCS 11197 as Secretarial Auditor of the Company for the FY 2025-26.
Change in Management · 14 Jul 2026, 11:44 pm
Goldline Pharma Appoints New Secretarial Auditor for FY26 Goldline Pharmaceutical Limited (BSE: 544759) has appointed M/s. Avinash Gandhewar & Associates, Practicing Company Secretaries, as its Secretarial Auditor. The appointment, effective from the board meeting on 14th Jul'26, is for the financial year 2025-26 (from 01st Apr'25 to 31st Mar'26). The appointed firm specializes in Company Law, Securities Laws, M&A, and IPOs. This is a key governance appointment ensuring compliance with SEBI regulations for the upcoming financial year.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 24 Jun 2026, 11:51 pm
Goldline Pharma Confirms Non-Applicability of Large Corporate Framework Goldline Pharmaceutical Limited (GLPL) has formally notified the BSE that it does not qualify as a 'Large Corporate' (LC) under SEBI's regulatory framework. The company is therefore not subject to the mandatory debt fundraising requirements for LCs. The filing also disclosed that its outstanding borrowings stood at INR 9.16 crores as of 31st Mar'26. As it is not an LC, details regarding credit ratings and potential penalties for borrowing shortfalls are not applicable to the company.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Swapan Khandelwal
Acquisition/ Disposal of Shares · 24 Jun 2026, 6:50 pm
Promoter Swapan Khandelwal Acquires Additional Stake in Goldline Pharmaceutical Promoter and Whole Time Director Swapan Khandelwal acquired 60,000 equity shares of Goldline Pharmaceutical Ltd through an open market purchase on 22nd Jun'26. This transaction represents 0.62% of the company's total paid-up share capital. Following the acquisition, Khandelwal's total shareholding has increased from 2,749,988 shares (28.65%) to 2,809,988 shares, raising his stake to 29.27%. This move signals growing promoter confidence in the company. The total equity share capital remains unchanged at 9,600,000 shares.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Swapan Khandelwal
Acquisition/ Disposal of Shares · 24 Jun 2026, 6:49 pm
Goldline Pharma Promoter Increases Stake via Open Market Purchase Mr. Swapan Khandelwal, a Promoter and Whole Time Director of Goldline Pharmaceutical, acquired 60,000 equity shares on 22nd Jun'26 through an open market purchase. This transaction, representing 0.62% of the company's paid-up capital, increased his total holding from 28.65% (2,749,988 shares) to 29.27% (2,809,988 shares). This move signals increased promoter confidence in the company. The disclosure was made on 23rd Jun'26 under SEBI (SAST) Regulations, 2011.
Disclosure under regulation 29 (2) of SEBI (SAST) Regulations, 2011
Others (Uncategorized) · 24 Jun 2026, 2:07 am
Promoter Increases Stake in Goldline Pharmaceutical via Open Market Purchase Mr. Swapan Khandelwal, a Promoter and Whole Time Director of Goldline Pharmaceutical, acquired 60,000 equity shares through an open market purchase on 22nd Jun'26. This transaction represents 0.62% of the company's total paid-up share capital. Following the acquisition, Mr. Khandelwal's total shareholding increased from 28.65% (2,749,988 shares) to 29.27% (2,809,988 shares). This purchase further consolidates the promoter group's position in the company.
Intimation of Appointment of M/s. Kunal Dutt & Associates, Practicing Company Secretaries, Membership No. FCS 8831 as Internal Auditor of the Company.
Change in Management · 10 Jun 2026, 12:36 am
Goldline Pharma Appoints Kunal Dutt & Associates as Internal Auditor Goldline Pharmaceutical Limited (BSE: 544759) has appointed M/s. Kunal Dutt & Associates as its new Internal Auditor, effective from the financial year 2026-27 onwards. The Board of Directors approved the appointment on 09 Jun'26, based on the recommendation of the Audit Committee. The appointed firm is not related to any Director or Key Managerial Personnel (KMP) of the company, ensuring independence. This move is a key update for the company's corporate governance framework.
Outcome of Board Meeting held today, i.e., 09th June, 2026 for approval of financial results for the half year and year ended 31st march, 2026.
Outcome · 10 Jun 2026, 12:30 am
Goldline Pharma FY26 Results & Internal Auditor Appointment Goldline Pharmaceutical reported FY26 standalone Profit After Tax (PAT) of ₹411.71 Lacs, a 45.2% YoY increase from ₹283.43 Lacs. Revenue from operations grew 11.2% YoY to ₹3,119.76 Lacs. For H2FY26 ended 31st Mar'26, PAT stood at ₹276.15 Lacs. The Board approved the audited financials on 09th Jun'26 and appointed M/s. Kunal Dutt & Associates as Internal Auditor from FY 2026-27 onwards. Basic EPS for FY26 was ₹5.97, up from ₹4.11 in FY25.
Outcome of Board Meeting held today, i.e. 09th June, 2026 for approval of financials results for the half year and year ended 31st March, 2026.
Financial Result · 10 Jun 2026, 12:24 am
Goldline Pharmaceutical Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lacs) ■ Revenue: 1,731 (+1573127.3% YoY | +24.6% QoQ) ■ EBITDA: 430 (+195577.3% YoY | +63.4% QoQ) ■ EBITDA Margin (%): 24.9 (-17512 bps YoY | +591 bps QoQ) ■ PAT: 276 (+250945.5% YoY | +103.7% QoQ) ■ EPS (INR): 4.00 (+3536.4% YoY | +104.1% QoQ)
Goldline Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/06/2026 ,inter alia, to consider and approve Standalone Audited ....
Intimation · 09 Jun 2026, 5:30 am
Goldline Pharma Board Meeting Set to Approve H2 and FY26 Financial Results Goldline Pharmaceutical Limited (BSE: 544759) has scheduled a Board of Directors meeting for Tue, 09-Jun-26. The primary agenda is to consider and approve the standalone audited financial results, including the statement of assets and liabilities, for the half-year and full-year ended 31-Mar-26. The outcome of the meeting will be disclosed separately. This is a key event for investors awaiting the company's full-year performance data.